Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera.

Saved in:
Bibliographic Details
Title: Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera.
Authors: Espeseth AS; Merck & Co., Inc., Rahway, New Jersey, USA., Yuan M; The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA., Citron M; Merck & Co., Inc., Rahway, New Jersey, USA., Reiserova L; The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA., Morrow G; The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA., Wilson A; The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA., Horton M; Merck & Co., Inc., Rahway, New Jersey, USA., Rukhman M; The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA., Kinek K; Merck & Co., Inc., Rahway, New Jersey, USA., Hou F; The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA., Li SL; The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA., Li F; Merck & Co., Inc., Rahway, New Jersey, USA., Choi Y; The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA., Heidecker G; Merck & Co., Inc., Rahway, New Jersey, USA., Luo B; Merck & Co., Inc., Rahway, New Jersey, USA., Wu G; Merck & Co., Inc., Rahway, New Jersey, USA., Zhang L; Merck & Co., Inc., Rahway, New Jersey, USA., Strable E; Merck & Co., Inc., Rahway, New Jersey, USA., DeStefano J; The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA., Secore S; Merck & Co., Inc., Rahway, New Jersey, USA., Mukhopadhyay TK; Merck & Co., Inc., Rahway, New Jersey, USA., Richardson DD; Merck & Co., Inc., Rahway, New Jersey, USA., Sayeed E; The International AIDS Vaccine Initiative, Inc. (IAVI), New York, USA., Welch LS; The International AIDS Vaccine Initiative, Inc. (IAVI), New York, USA; Currently at Clover Biopharmaceuticals, Boston, Massachusetts, USA., Bett AJ; Merck & Co., Inc., Rahway, New Jersey, USA., Feinberg MB; The International AIDS Vaccine Initiative, Inc. (IAVI), New York, USA., Gupta SB; The International AIDS Vaccine Initiative, Inc. (IAVI), New York, USA., Cooper CL; The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA., Parks CL; The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA. Electronic address: cparks@iavi.org.
Source: EBioMedicine [EBioMedicine] 2022 Aug; Vol. 82, pp. 104203. Date of Electronic Publication: 2022 Jul 30.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3964 (Electronic) Linking ISSN: 23523964 NLM ISO Abbreviation: EBioMedicine Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2352-3964
DOI:10.1016/j.ebiom.2022.104203